• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump

    1/28/25 8:44:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond.

    With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and retention rates, and foster proactive child and family health. By addressing gaps across the spectrum, from fertility to postpartum support and parental leave navigation, the company helps eliminate fragmentation and enhances multi-dimensional outcomes for families.

    "The acquisition of BenefitBump extends our ability to provide compassionate and dedicated support to give members more confidence along their parenting journey," said Pete Anevski, Chief Executive Officer, Progyny. "BenefitBump's high-touch, guided support integrates seamlessly into our existing patient care model and aligns with our commitment to improving member well-being through a higher standard of care."

    Alongside the offerings Progyny is known for across preconception, fertility, pregnancy, postpartum, and menopause, the enhanced suite of services will include:

    • Clinical social worker-led parental wellness program
    • Comprehensive parental leave and benefits navigation
    • Care and resource navigation for child behavior concerns and neurodiverse care
    • Clinician-facilitated peer support groups

    "Navigating employee benefits and leave programs is complex and adds unnecessary stress for families. Every new parent will experience leave, yet it has been an underserved area. BenefitBump was built by listening to the challenges and needs of parents, with the goal of easing their anxiety and ensuring employers and employees get the most value from family support investments," said Scott Liebman, Founder, BenefitBump. "We're thrilled to join Progyny, an innovator and leader in the family building space, and together provide the holistic support that families deserve."

    For more information about Progyny visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a transformative fertility, family building and women's health benefits solution, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. 

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.  

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. 

    For Further Information, Please Contact:

    Investors:

    James Hart

    [email protected]

    Media:

    Alexis Ford

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scott Cheryl sold $59,037 worth of shares (2,675 units at $22.07), decreasing direct ownership by 16% to 14,112 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/12/25 5:07:13 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • EVP, GC Swartz Allison covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.41% to 82,095 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/5/25 5:23:09 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.47% to 72,172 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/5/25 5:18:40 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care